New Approval for Metastatic Breast Cancer: Alpelisib
This past May, the FDA approved the targeted therapy alpelisib (Piqray) to treat certain hormone receptor-positive, HER2-negative breast cancers in postmenopausal women and in men. Up to 40 percent of people with metastatic hormone receptor-positive, HER2-negative breast cancer could be eligible to get the treatment, which targets a mutation on the PIK3CA gene. Join us on July 22 to hear from our speaker Adam Brufsky, MD, PhD about this new medicine, how to access it and some of the side effects that come with it.
Alpelisib is the first PI3K inhibitor approved for breast cancer. Learn more about the FDA approval.
About Our SpeakerAdam M. Brufsky, MD, PhD, is professor of medicine at the University of Pittsburgh School of Medicine and serves as the associate director of clinical investigation for the University of Pittsburgh Cancer Institute. He is board certified in internal medicine and medical oncology by the American Board of Internal Medicine, and is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research. Read more.